

Use Case



Cost-Effectiveness Analysis (CEA)

The Purpose

To conduct cost effectiveness analysis from payer perspective to assess willingness to pay as per ICER threshold guidelines.

About the Client

 **INDUSTRY**
Mid-size Pharma


 **LOCATION**
US

 **THERAPEUTIC AREA**
Oncology

Client Requirement

- To develop an economic model for comparing Client Intervention to Standard of Care.
- To calculate the Incremental Cost-Effectiveness Ratio (ICER) by conducting cost-effectiveness analysis.
- To create a Markov model-based simulation of the target patient cohort.

The Excelra Approach



Excelra's Contribution

Calculated the ICER for the intervention and conducted Tornado analysis to identify factors with highest impact on ICER.

The CEA model developed was used for communicating the value of the intervention to payers and providers.

Excelra's Value Evidence Service Portfolio



Outcomes Research



Value Evidence Communication



Epidemiology Modelling



RWE & Big Data Realization



Economic Modelling



SLR & Meta-Analysis

For more information, visit https://www.excelra.com/value_evidence/#economic_modelling



About Excelra

Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyze large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 90 global clients including 15 of the top 20 large Pharma.